Abstract
Peripheral cytopenias are common in patients with agnogenic myeloid metaplasia (AMM). They are an important cause of morbidity and mortality, and their treatment is difficult. We report on 4 patients with AMM and severe cytopenia treated with danazol (400-600 mg/ day). Three of them became independent of red blood cell (RBC) transfusion, while the other had a slight reduction in RBC requirement. In addition, correction of thrombocytopenia and disappearance of splenomegaly were observed in 1 and 2 patients, respectively. No side effects were observed. In our experience, danazol appears effective and safe in the subset of patients with AMM whose disease is mainly characterized by bone-marrow failure. These data warrant further studies to evaluate this treatment and explore its mechanism of action.
References
Apr 1, 1991·British Journal of Haematology·E A StadtmauerD B Cines
Nov 1, 1989·Annals of Internal Medicine·Y S AhnW J Harrington
Feb 26, 1987·The New England Journal of Medicine·A D SchreiberD B Cines
Mar 1, 1985·Annals of Internal Medicine·Y S AhnL M Pall
Jun 9, 1983·The New England Journal of Medicine·Y S AhnA G So
May 1, 1994·British Journal of Haematology·E WattelP Fenaux
Mar 1, 1994·British Journal of Haematology·K P DallaR K Shadduck
Sep 1, 1993·British Journal of Haematology·L CatalanoB Rotoli
Citations
Feb 13, 2001·European Journal of Haematology·A TefferiM G Chen
Jun 20, 2002·European Journal of Haematology·G DamajO Hermine
Dec 13, 2006·Acta Haematologica·S N TsiaraK L Bourantas
Apr 27, 2000·The New England Journal of Medicine·A Tefferi
Nov 8, 2001·Leukemia & Lymphoma·R A Mesa, A Tefferi
Feb 24, 2005·British Journal of Haematology·Francisco Cervantes
Jun 15, 2005·British Journal of Haematology·Francisco CervantesEmili Montserrat
Mar 23, 2011·Hematology·Vincenzo FontanaYeon S Ahn
May 18, 2016·Expert Opinion on Drug Safety·J M O'SullivanC N Harrison
Jun 3, 2017·Expert Review of Hematology·Iram SaeedClaire N Harrison
Nov 15, 2002·International Journal of Hematology·Ruben A Mesa
Apr 29, 2010·Current Hematologic Malignancy Reports·Ruben A Mesa
May 17, 2003·Leukemia·R A MesaS H Kaufmann
Feb 16, 2006·Hematological Oncology·John T Reilly
May 10, 2001·Journal of Surgical Oncology·G AkpekL Weintraub
Jun 2, 2012·British Journal of Haematology·John T ReillyUNKNOWN Writing group: British Committee for Standards in Haematology
Oct 2, 2012·Molecular Diagnosis & Therapy·Raoul TibesRuben A Mesa